A detailed history of Baker Bros. Advisors LP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Baker Bros. Advisors LP holds 2,997,772 shares of FATE stock, worth $10.7 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
2,997,772
Previous 1,818,181 64.88%
Holding current value
$10.7 Million
Previous $13.3 Million 26.32%
% of portfolio
0.13%
Previous 0.17%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$3.26 - $7.08 $3.85 Million - $8.35 Million
1,179,591 Added 64.88%
2,997,772 $9.83 Million
Q1 2024

May 15, 2024

BUY
$3.54 - $8.35 $6.44 Million - $15.2 Million
1,818,181 New
1,818,181 $13.3 Million
Q1 2023

May 15, 2023

BUY
$4.24 - $11.12 $6.17 Million - $16.2 Million
1,456,022 Added 675.04%
1,671,717 $9.53 Million
Q3 2022

Nov 14, 2022

BUY
$21.04 - $36.06 $4.54 Million - $7.78 Million
215,695 New
215,695 $4.83 Million

Others Institutions Holding FATE

About FATE THERAPEUTICS INC


  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $346M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.